Upfront vs Milestone: What a $3.2B Licensing Deal Actually Pays
In a technology licensing deal, only the upfront payment is certain at signing. Korean biotech deals have averaged upfronts of 0.48-5.8% of headline value, while overseas deals range from 1.6% to 82%.